Organization
Centre Hospitalier de l’Université de Montréal/CRCHUM
8 abstracts
Abstract
Association of baseline characteristics with adverse events (AEs) in the PROpel trial of olaparib (ola) plus abiraterone (abi) as first-line (1L) treatment for metastatic castration-resistant prostate cancer (mCRPC).Org: Centre Hospitalier de l’Université de Montréal/CRCHUM, Centro Integrado de Oncologia de Curitiba, Radboud Universitair Medisch Centrum, Southampton General Hospital, Centre Hospitalier de Quimper,
Abstract
EMBARK post hoc analysis of sexual activity (SA) patient-reported outcomes (PROs) in patients (pts) who were sexually active or interested in sex at baseline (BL).Org: Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Memorial Sloan Kettering Cancer Center, Vancouver Prostate Centre, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) Dino Amadori,
Abstract
Prevalence of intra-patient inter-metastatic heterogeneity in mCRPC patients based on triple-tracer PET imaging: The 3TMPO study.Org: Laval University, CHU de Quebec-Universite Laval, Division of Urology, Department of Surgery, Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, Centre Hospitalier de l’Université de Montréal (CHUM/CRCHUM), University of Sherbrooke,
Abstract
A phase I/II dose escalation and expansion trial to evaluate safety and preliminary efficacy of BNT141 in patients with claudin-18.2-positive solid tumors.Org: Centre Hospitalier de l’Université de Montréal (CHUM), Centre de Recherche du CHUM (CRCHUM), Université de Montréal, Princess Margaret Cancer Centre, The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX,
Abstract
Association of dynamic changes in serological markers with survival in de novo metastatic hormone-sensitive prostate cancer.Org: Rush University Medical Center, Case Western Reserve University School of Medicine, The Ottawa Hospital Research Institute, University of Ottawa, UCLA Department of Radiation Oncology,
Abstract
Training and validation of a model predicting clusters of long-term cancer-related behavioral symptoms (CRBS) after breast cancer (BC).Org: INSERM Unit 981, Gustave Roussy Département d'Organisation du Parcours Patient, Villejuif, France, Breast Cancer Survivorship Group, INSERM Unit 981, Gustave Roussy, Villejuif, France, Institut Curie, Saint Cloud, France,
Abstract
A first-in-human, open-label, phase I trial of daily oral PCLX-001, an NMT inhibitor, in patients with relapsed/refractory B-cell lymphomas and advanced solid tumors.Org: Cross Cancer Institute, Centre Hospitalier de l’Université de Montréal/CRCHUM, Princess Margaret - University Health Network, BC Cancer Centre for Lymphoid Cancer, Pacylex Pharmaceuticals, Inc.,
Abstract
ASSOCIATION OF SPONDYLOARTHROPATHY WITH MULTIPLE SCLEROSIS : 17 CASESOrg: University Teaching Hospital Bouake (CHU de Bouake), Centre Hospitalier de l’Université de Montréal/CRCHUM, Office of Data Services at Division of Digital Health, Lariboisiere Hospital - APHP,